ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
13.64
+0.01 (0.07%)
At close: Aug 27, 2025, 4:00 PM
13.91
+0.27 (1.98%)
After-hours: Aug 27, 2025, 6:05 PM EDT
ImageneBio Revenue
ImageneBio had revenue of $4.30M in the twelve months ending June 30, 2025. In the year 2024, ImageneBio had annual revenue of $3.50M, down -56.04%.
Revenue (ttm)
$4.30M
Revenue Growth
-56.04%
P/S Ratio
35.85
Revenue / Employee
n/a
Employees
n/a
Market Cap
152.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.50M | -4.46M | -56.04% |
Dec 31, 2023 | 7.96M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMA News
- 26 days ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - GlobeNewsWire
- 5 weeks ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 6 weeks ago - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewsWire
- 6 weeks ago - Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals - GlobeNewsWire
- 8 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewsWire
- 10 months ago - Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Ikena Oncology Reports Second Quarter 2024 Financial Results - GlobeNewsWire